374 related articles for article (PubMed ID: 16146202)
1. Changes in gastric ECL cells and parietal cells after long-term administration of high-dose omeprazole to patients with Barrett's esophagus.
Nishi T; Makuuchi H; Weinstein WM
Tokai J Exp Clin Med; 2005 Jul; 30(2):117-21. PubMed ID: 16146202
[TBL] [Abstract][Full Text] [Related]
2. Histopathology of the gastric oxyntic mucosa in two different patient groups during long-term treatment with omeprazole.
Hage E; Hendel L; Gustafsen J; Hendel J
Eur J Gastroenterol Hepatol; 2003 Jul; 15(7):781-9. PubMed ID: 12811309
[TBL] [Abstract][Full Text] [Related]
3. Effect of a gastrin/cholecystokinin B receptor antagonist, S-0509, on the omeprazole-induced proliferation of gastric mucosa in rats.
Ono M; Sato H; Kazumori H; Yuki M; Rumi MA; Ortega-Cava CF; Ishihara Y; Ishihara S; Adachi K; Kinoshita Y
J Lab Clin Med; 2003 Dec; 142(6):364-71. PubMed ID: 14713888
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up and factors predictive of recurrence in Barrett's esophagus treated by argon plasma coagulation and acid suppression.
Kahaleh M; Van Laethem JL; Nagy N; Cremer M; Devière J
Endoscopy; 2002 Dec; 34(12):950-5. PubMed ID: 12471537
[TBL] [Abstract][Full Text] [Related]
5. Treatment with lansoprazole also induces hypertrophy of the parietal cells of the stomach.
Stolte M; Meining A; Seifert E; Alexandridis T
Pathol Res Pract; 2000; 196(1):9-13. PubMed ID: 10674267
[TBL] [Abstract][Full Text] [Related]
6. Fundic metaplasia with parietal cell hyperplasia of the antrum: a lesion possibly associated with long term use of omeprazole.
Declich P; Ambrosiani L; Prada A; Bortoli A; Bellone S; Tavani E; Gozzini C
Am J Gastroenterol; 1999 Aug; 94(8):2317-9. PubMed ID: 10445579
[No Abstract] [Full Text] [Related]
7. Effect of up to 3 years of high-dose lansoprazole on Barrett's esophagus.
Sampliner RE
Am J Gastroenterol; 1994 Oct; 89(10):1844-8. PubMed ID: 7942680
[TBL] [Abstract][Full Text] [Related]
8. Effects of long-term treatment with lansoprazole and omeprazole on serum gastrin and the fundic mucosa.
Arroyo Villarino MT; Lanas Arbeloa A; Esteva Díaz F; Ortego Fernández de Retana J; Sainz Samitier R
Rev Esp Enferm Dig; 1997 May; 89(5):347-56. PubMed ID: 9190140
[TBL] [Abstract][Full Text] [Related]
9. Time-course of development and reversal of gastric endocrine cell hyperplasia after inhibition of acid secretion. Studies with omeprazole and ranitidine in intact and antrectomized rats.
Larsson H; Carlsson E; Håkanson R; Mattsson H; Nilsson G; Seensalu R; Wallmark B; Sundler F
Gastroenterology; 1988 Dec; 95(6):1477-86. PubMed ID: 3181674
[TBL] [Abstract][Full Text] [Related]
10. Omeprazole: its influence on gastric acid secretion, gastrin and ECL cells.
Larsson H; Håkanson R; Mattsson H; Ryberg B; Sundler F; Carlsson E
Toxicol Pathol; 1988; 16(2):267-72. PubMed ID: 3187355
[TBL] [Abstract][Full Text] [Related]
11. Predictors for squamous re-epithelialization of Barrett's esophagus after endoscopic biopsy.
Amano Y; Kushiyama Y; Yuki T; Takahashi Y; Chinuki D; Ishimura N; Furuta K; Ishihara S; Adachi K; Maruyama R; Kinoshita Y
J Gastroenterol Hepatol; 2007 Jun; 22(6):901-7. PubMed ID: 17565646
[TBL] [Abstract][Full Text] [Related]
12. Gastrin has a specific proliferative effect on the rat enterochromaffin-like cell, but not on the parietal cell: a study by elutriation centrifugation.
Bakke I; Qvigstad G; Brenna E; Sandvik AK; Waldum HL
Acta Physiol Scand; 2000 May; 169(1):29-37. PubMed ID: 10759608
[TBL] [Abstract][Full Text] [Related]
13. Barrett's ulcer: response to standard dose ranitidine, high dose ranitidine, and omeprazole.
Lee FI; Isaacs PE
Am J Gastroenterol; 1988 Sep; 83(9):914-6. PubMed ID: 3414644
[TBL] [Abstract][Full Text] [Related]
14. Effects of hydrochloric acid on the development of enterochromaffin-like (ECL) cell hyperplasia in the rat stomach induced by omeprazole.
Fujii T; Oishi Y; Fujihira S; Matsuo M; Tomoi M
J Toxicol Sci; 1993 Nov; 18(4):257-63. PubMed ID: 8295229
[TBL] [Abstract][Full Text] [Related]
15. Fundic gland polyps developing during omeprazole therapy.
el-Zimaity HM; Jackson FW; Graham DY
Am J Gastroenterol; 1997 Oct; 92(10):1858-60. PubMed ID: 9382052
[TBL] [Abstract][Full Text] [Related]
16. Marked increase in gastric acid secretory capacity after omeprazole treatment.
Waldum HL; Arnestad JS; Brenna E; Eide I; Syversen U; Sandvik AK
Gut; 1996 Nov; 39(5):649-53. PubMed ID: 9026477
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of Barrett esophagus with argon plasma coagulation with acid suppression--a prospective study].
Martin WR; Jakobs R; Spiethoff A; Maass S; Riemann JF
Z Gastroenterol; 1999 Sep; 37(9):779-84. PubMed ID: 10522363
[TBL] [Abstract][Full Text] [Related]
18. Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence.
Cooper BT; Chapman W; Neumann CS; Gearty JC
Aliment Pharmacol Ther; 2006 Mar; 23(6):727-33. PubMed ID: 16556174
[TBL] [Abstract][Full Text] [Related]
19. The dose of omeprazole required to achieve adequate intraesophageal acid suppression in patients with gastroesophageal junction specialized intestinal metaplasia and Barrett's esophagus.
Watson JT; Moawad FJ; Veerappan GR; Bassett JT; Maydonovitch CL; Horwhat JD; Wong RK
Dig Dis Sci; 2013 Aug; 58(8):2253-60. PubMed ID: 23824407
[TBL] [Abstract][Full Text] [Related]
20. Transcriptomes of purified gastric ECL and parietal cells: identification of a novel pathway regulating acid secretion.
Lambrecht NW; Yakubov I; Zer C; Sachs G
Physiol Genomics; 2006 Mar; 25(1):153-65. PubMed ID: 16403840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
